Acelyrin Inc 's (SLRN) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Acelyrin Inc   (NASDAQ: SLRN)
 



  Acelyrin Inc Outlook

On May 9 2024 the Acelyrin Inc provided following guidance

Acelyrin Inc. has provided a business update regarding the progress of their clinical trials. The company has successfully completed enrollment in the Phase 3 trial for izokibep in hidradenitis suppurativa. Additionally, enrollment in the Phase 2b/3 trial for uveitis is expected to be completed by the end of this month.

The top line data for both trials is now anticipated to be available by the end of the third quarter and fourth quarter of 2024, respectively. These milestones mark significant progress in the development of Acelyrin Inc.'s potential treatments for these challenging medical conditions.

The company remains committed to advancing research and development efforts to bring innovative therapies to patients in need. Stay tuned for further updates on the progress of Acelyrin Inc.'s clinical trials and upcoming milestones.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.